Penile Cancer Survival Rates: How Common It Is, What the Numbers Mean, and Whether Penile Cancer Is Curable

Almost every man who is told he has penile cancer types the same thing into a search bar within a day or two. He wants to know his odds.

The numbers in this guide come from the American Cancer Society, the National Cancer Institute, the Surveillance, Epidemiology, and End Results program (called SEER, the main United States cancer registry), Cancer Research UK, and the 2026 penile cancer guidelines from the European Association of Urology and the American Society of Clinical Oncology.

How Common Is Penile Cancer?

Penile cancer is rare in the United States. The American Cancer Society estimates about 2,260 new penile cancers and about 450 deaths in the United States in 2026. Fewer than 1 in 100,000 men in the United States are diagnosed each year, and penile cancer accounts for fewer than 1% of all cancers. The National Cancer Institute puts the United States incidence rate at less than 1 per 100,000 men per year, and its treatment summary listed about 2,190 new cases and about 510 deaths for 2025. Small year-to-year differences in these estimates are normal, because they are projections rather than counts.

Rarity has practical effects that go beyond statistics. Many family doctors will see only one or two cases in an entire career, so a lesion on the penis is often treated as an infection or a skin condition first. Many men have never heard the words "penile cancer" before the day they hear them about themselves. And because there are so few patients, large clinical trials are hard to run, which is one reason care is best delivered at a center that sees this cancer regularly.

The picture looks very different in other parts of the world. The European Association of Urology reports an overall incidence of roughly 0.94 per 100,000 men in Europe and 0.5 per 100,000 in the United States. In South America, Southeast Asia, and parts of Africa, the incidence is much higher, and penile cancer can account for 1% to 2% of all cancers in men. Reported yearly age-adjusted rates include 0.7 to 3.0 per 100,000 in India and 8.3 per 100,000 in Brazil, with higher rates in parts of Africa such as Uganda. The lowest reported rate is among Israeli Jewish men, at 0.3 per 100,000 per year. Older textbooks and websites sometimes claim penile cancer makes up 10% to 20% of male cancers in low-income countries. Current guideline sources do not support that figure, so treat it with caution if you come across it.

Incidence also appears to be rising in several wealthy countries, which surprises many people. The European Association of Urology states that Western developed countries have seen an increase in incidence, most likely driven by higher rates of human papillomavirus infection, the same trend seen in throat cancer. Reported examples include a rise in one German region from 0.86 per 100,000 in 2000 to 2.67 per 100,000 in 2018, and a rise in the Netherlands from 0.92 to 1.83 per 100,000 per year between 1990 and 2020. United States registry data showed an estimated yearly change of about 3.5% from 2004 to 2016.

The United Kingdom shows the same direction. Cancer Research UK reports that penile cancer incidence rates in males have increased by more than two-fifths, about 42%, since the early 1990s, and by about a fifth, roughly 20%, in the last decade. They project a further 8% increase by the period from 2038 to 2040, reaching around 1,100 new cases a year. Rising incidence is a reason to take a stubborn sore or patch seriously, not a reason to panic, because the absolute risk for any individual man remains very low. You can read more about what raises risk in our guide to risk factors for penile cancer.

Age matters too. The American Cancer Society reports that the average age at the time of diagnosis is about 60 years. A published analysis of United States registry data reported a median age at diagnosis of 68 years, and found that 57.8% of patients were 65 or older when they were diagnosed. Penile cancer does occur in younger men, and it becomes more common as men get older. If you have just been diagnosed and feel like the only one, our guide to penile cancer support lists places where other men and their partners can be found.

What Is the Survival Rate for Penile Cancer?

Start with what the phrase means, because the wording confuses almost everyone. A relative survival rate compares men who have the same type and stage of penile cancer to men in the general population. As the American Cancer Society explains it, if the five-year relative survival rate for a stage is 80%, that means men with that cancer are, on average, about 80% as likely as men without that cancer to still be alive five years after diagnosis. It is a comparison, not a countdown, and it is not a limit on how long anyone lives.

Three limitations are built into every survival rate, and they matter more in a rare cancer where the numbers come from small groups of men:

• They describe the stage at diagnosis only: The figures apply to how far the cancer had spread when it was first found. They do not apply later if the cancer grows, spreads, or comes back after treatment, and they do not describe your situation after treatment has already worked.

• They leave out almost everything about you: Survival rates are grouped only by how far the cancer had spread. Your age, your general health, your other medical conditions, the microscopic subtype of your tumor, and how well the cancer responds to treatment all affect your outlook, and none of them appear in the numbers.

• They are already out of date the day they are published: The numbers come from men diagnosed and treated at least five years ago. Treatment has improved since then, so men being diagnosed now may do better than the published figures suggest.

Stages of Penile Cancer

After penile cancer is diagnosed, your doctor will figure out the stage. The stage tells you how much the cancer has grown and whether it has spread. Your doctor will want to find out the stage of your cancer to help decide what type of treatment is best for you.

Your cancer can be stage 0, 1, 2, 3, or 4. The lower the number, the less the cancer has spread. A higher number, like stage 4, means the cancer has spread farther. American Cancer Society

Stage 0
This is the earliest stage. Cancer cells are found only in the top layers of skin. Doctors also call this carcinoma in situ, or CIS. American Cancer Society

Stage I
The cancer has grown just below the top layer of skin. It has not spread to lymph nodes or other parts of the body.

Stage II
The cancer has grown deeper into the penis. It may have reached the erectile tissue or the urethra (the tube urine passes through). It still has not spread to lymph nodes.

Stage III
The cancer has spread to lymph nodes in the groin. Doctors split this into two smaller groups based on how many lymph nodes are affected and whether the cancer is on one or both sides of the body.

Stage IV
This is the most advanced stage. Stage 4 can include different types of cancer growth — it may mean the cancer has grown into nearby body parts like the scrotum or pelvic bone, spread to lymph nodes deep in the pelvis, or reached distant organs such as the lungs, liver, or bones.

How doctors decide the stage

Doctors use a system called TNM to figure out the stage. The stage is based on how much the cancer has grown in the penis or into nearby structures. It also tells if the cancer has spread to other parts of your body.

• T (Tumor): How large the tumor is and how deep it has grown

• N (Nodes): Whether the cancer has reached nearby lymph nodes

• M (Metastasis): Whether the cancer has spread to distant parts of the body

The grade of the cancer cells, meaning how different they look from normal cells, can also affect the stage of some early-stage penile cancers.

SEER does not group penile cancers by stage 1, stage 2, and stage 3. It uses three broader groups:

• Localized means the cancer is confined to the penis, with a 79% survival rate

• Regional means it has spread outside the penis to nearby structures or nearby lymph nodes (small glands that filter fluid and help fight infection), with a 57% survival rate

• Distant means it has spread to faraway parts of the body such as the lungs, liver, or bones, with a 10% survival rate

Survival rate based on men diagnosed between 2015 and 2021, the American Cancer Society.

It also helps to know the status of the cancer in most men. In a published analysis of penile squamous cell carcinomas recorded in United States registries between 2000 and 2018,

• 55.4% had local disease

• 41.0% had regional disease

• 3.6% had distant disease

In other words, most men are diagnosed before the cancer has traveled far, and only a small minority are diagnosed with distant spread. The single largest group falls in the category with the best reported outcome.

Lymph node status is the single strongest predictor of survival in penile cancer. The European Association of Urology puts it plainly: the presence and extent of lymph node involvement is the most important prognostic factor in penile cancer, and cure can be achieved when limited disease is confined to the regional nodes. This is why your doctor will carefully feel both groins, order imaging, and may recommend a sentinel lymph node biopsy or a groin lymph node dissection even when nothing can be felt. It is also why cancer spread beyond the capsule of a node, or into the pelvic nodes, changes the plan so much. Our guide to penile cancer stages walks through how the N categories are assigned.

Is Penile Cancer Curable?

Yes, penile cancer is often curable, and it is most curable when it is found early and is still confined to the penis. The National Cancer Institute states that when diagnosed early, at stage 0, stage I, or stage II, penile cancer is highly curable, and it says outright that stage I penile cancer is curable. It also says that curability decreases sharply for stage III and stage IV disease. Both halves of that sentence are true at once, and holding both is the realistic way to think about this cancer.

Three words get used loosely in clinic, so it is worth separating them.

• Cure: means the cancer is gone and is not expected to come back, and doctors usually only use it with confidence after years of clean follow-up.

• Remission: means the signs and symptoms of cancer have decreased or disappeared, which may be partial or complete, and a complete remission can later turn out to have been a cure.

• No evidence of disease (NED): It means that with the tests available, nothing cancerous can be found today. It does not promise that nothing microscopic remains.

Many men live for years, and many for the rest of their lives, in that state. If your team uses one of these words, it is fair to ask which one they mean and why.

Cancer that has reached the lymph nodes is more serious, but it is not automatically incurable, and this is one of the most important things to understand about penile cancer. The European Association of Urology states that cure can be achieved in limited lymph node disease confined to the regional nodes, that radical lymph node dissection is the treatment of choice, and that in low volume node disease this surgery is curative with a suggestion of outcomes equivalent to men who had no node disease at all. For more extensive disease, treatment combines surgery with chemotherapy or radiation. In a phase II trial of chemotherapy given before surgery in men with clinically advanced groin or pelvic nodes, half of the 30 men responded, three had no cancer left in the surgical specimen, and long-term disease-free survival was seen in 67% of the men who responded. The guidelines are also honest about the other side of that coin: surgery alone will rarely cure a man with fixed or pelvic node disease, which is exactly why the combined approach is offered.

Things change when penile cancer has spread to distant organs. The National Cancer Institute states that no standard treatment exists that is curative for stage IV penile cancer, and that therapy is directed at palliation, meaning relief of symptoms and control of the disease. First treatment is usually chemotherapy that contains a platinum drug, sometimes as a combination of three drugs and sometimes as a gentler two-drug combination. Effective options after that are genuinely lacking, and second treatments in published studies have been associated with a median overall survival of six months or less. Immunotherapy trials in advanced penile cancer have produced low response rates, though some of those responses lasted a long time. Because of that, the guideline panel strongly recommends that every man with advanced penile squamous cell carcinoma enroll in a clinical trial where one is available. Our guide to joining a clinical trial for penile cancer explains how to look for one.

At that stage, the goal of treatment shifts from cure to control, and that shift deserves to be discussed openly rather than avoided. Control can mean shrinking a tumor so it stops bleeding or blocking urine, using radiation to relieve pain, treating symptoms directly, and protecting the parts of daily life that matter most to you. Palliative care is not the same as hospice, and it can run alongside cancer treatment from the beginning. Men who get symptom-focused care early often feel better and cope better. It is entirely reasonable to ask your oncologist for a palliative care referral while you are still on active treatment.

Now the part you can actually influence. The most changeable factor in penile cancer outcomes is how long a man waits before he gets examined. Published reviews report that up to 50% of men with penile cancer delayed seeking medical attention for the lesion for as long as a year, driven by embarrassment, guilt, fear, denial, and neglect, and that an estimated 25% of penile cancers are first diagnosed as something harmless. Early tumors are usually painless and usually do not affect urination or erections, which makes waiting feel safe when it is not. In one study of 254 men, a delay of more than three months was linked to worse tumor features, a lower chance of keeping the penis, and poorer sexual function afterward, and a delay of more than six months was linked to worse two-year survival. The European Association of Urology cites a small series in which men who reached groin surgery within six months of treatment for the primary tumor had a five-year cancer-specific survival of 91%, compared with 13% for men who reached it later.

So the practical message is short. If something on your penis has not cleared within a few weeks, ask for a biopsy rather than another cream, and ask to be seen by a urologist who treats this cancer or at a center that sees it regularly. Nothing about this cancer means you did anything wrong, and nothing about it makes an appointment something to be ashamed of. Early evaluation and specialist care are the two levers that move outcomes most, and both are available to you today. Our guides on penile cancer symptoms, how penile cancer is diagnosed, and penile cancer treatment explain what to expect at each step, and your own care team remains the right place to take every decision.

Sources:

• Survival Rates for Penile Cancer, American Cancer Society

• SEER Explorer, Surveillance, Epidemiology, and End Results Program, National Cancer Institute

• EAU and ASCO Guidelines on Penile Cancer, Epidemiology, Aetiology and Pathology, European Association of Urology

• Survival for Penile Cancer, Cancer Research UK

• Patterns of Treatment and Outcomes in Older Men With Penile Cancer, a SEER Dataset Analysis, Frontiers in Oncology

• Risk Factors and Negative Consequences of Patient's Delay for Penile Carcinoma, World Journal of Surgical Oncology